Sudden cardiac death in a young person can appear completely unexpected. In some families, however, there may be an inherited electrical disorder quietly increasing the risk of dangerous heart rhythms.
One such condition is catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited arrhythmia that can cause fainting, ventricular tachycardia and, in severe cases, cardiac arrest or sudden cardiac death. CPVT is particularly important because the heart may appear structurally normal and a routine resting ECG can be normal between episodes.
One of the most important genes associated with CPVT is RYR2, which encodes the cardiac ryanodine receptor, a protein involved in regulating calcium release inside heart muscle cells. Pathogenic variants affecting RYR2 can disrupt calcium handling and contribute to abnormal heart rhythms, particularly during physical exertion or emotional stress.
This makes RYR2 genetic testing an important component of the evaluation of appropriately selected patients with suspected inherited arrhythmia.
What Is CPVT?
CPVT is an inherited disorder of the heart’s electrical system. Unlike many structural heart diseases, CPVT may occur in people whose heart structure is otherwise normal.
The characteristic problem is exercise- or emotion-induced ventricular arrhythmia. Symptoms can include:
- Fainting during exercise
- Fainting during intense emotional stress
- Palpitations
- Seizure-like episodes caused by an abnormal heart rhythm
- Cardiac arrest
- Sudden cardiac death
Symptoms often begin during childhood or adolescence, although later presentations can occur. Gene Reviews reports that the average age of initial symptoms is approximately 7–12 years, while sudden death can occasionally be the first
This is why unexplained exertional fainting in a child, teenager or young adult should not automatically be attributed to dehydration, anxiety or a neurological problem without appropriate medical assessment.
Why Is the RYR2 Gene Important?
The RYR2 gene provides instructions for making the cardiac ryanodine receptor, an important calcium-release channel in heart muscle cells.
Calcium is fundamental to normal cardiac contraction. During each heartbeat, carefully controlled calcium movement helps cardiac muscle cells contract and relax.
Certain pathogenic RYR2 variants can interfere with this process. Under increased sympathetic stimulation—such as during exercise or intense emotional stress—abnormal calcium handling can promote ventricular arrhythmias.
RYR2 is the most common established genetic cause of typical CPVT. Expert consensus identifies RYR2 as a gene with definite evidence for association with CPVT, with RYR2-related disease accounting for a substantial proportion of genetically identified cases
Why Can CPVT Be Difficult to Detect?
A normal resting ECG does not necessarily exclude CPVT
This is one of the most clinically important features of the condition.
A person with CPVT may have a normal resting ECG, while exercise or adrenergic stimulation can reveal characteristic ventricular arrhythmias. Exercise testing may therefore be particularly informative when CPVT is suspected.
This creates a diagnostic challenge.
A young person may feel perfectly well at rest, have a normal routine ECG and still be vulnerable to exercise-triggered ventricular arrhythmia.
Symptoms may be mistaken for other conditions
Exertional fainting can have many causes. Some patients may initially be evaluated for neurological disorders, dehydration, vasovagal syncope or psychological causes.
A detailed history is therefore essential.
Questions about when the episode occurred, whether it followed exercise or emotional stress, whether there were palpitations, and whether relatives have experienced unexplained fainting or sudden death can provide important clues.
When Should RYR2 Genetic Testing Be Considered?
Genetic testing can be viewed as a general screening test for everyone.
Current cardiac genetic-testing consensus recommends molecular testing for established CPVT susceptibility genes—including RYR2, CASQ2, CALM1–3, TRDN and TECRL—when a patient meets appropriate clinical criteria for CPVT. RYR2 testing can therefore be particularly relevant when clinical history and cardiac evaluation raise suspicion of CPVT.
Potential clinical situations that may prompt specialist evaluation include:
Exercise-related fainting
Unexplained syncope occurring during running, sports or other physical activity deserves careful cardiac evaluation, particularly in a young person.
A family history of sudden cardiac death
A history of unexplained sudden death in a young relative can be an important clue to an inherited cardiac condition.
Exercise-triggered ventricular arrhythmia
Patients with documented ventricular tachycardia or characteristic arrhythmias during exercise may warrant genetic evaluation.
A known familial RYR2 pathogenic variant
Once a disease-causing variant has been identified in a family, targeted testing of appropriate relatives can help identify family members who may require specialist cardiac assessment. Expert consensus supports cascade genetic testing in such circumstances.
What Happens When an RYR2 Pathogenic Variant Is Identified?
Finding a clinically significant RYR2 variant can have implications beyond the individual tested.
Because CPVT can run in families, identification of a disease-causing variant may lead to cascade testing and cardiac evaluation of appropriate relatives. Expert consensus recommends variant-specific testing for relevant family members after a causative variant has been identified.
This creates an opportunity for earlier identification of relatives who may otherwise remain undiagnosed.
Importantly, a genetic result should be communicated through appropriate medical and genetic counselling. Patients and families need to understand what the result means, what it does not mean, and whether additional cardiac assessment is appropriate.
Could RYR2 Testing Help Reduce Delayed Recognition of CPVT?
Potentially, yes—but only when used in the right clinical context.
CPVT can be difficult to recognize because symptoms may occur intermittently, the resting ECG may be normal, and the condition may first become apparent during exercise or emotional stress.
Genetic testing can provide an additional source of evidence when CPVT is clinically suspected. It may also help identify at-risk relatives after a disease-causing familial variant has been established.
The greatest value comes from integrating genomics with phenotype, rather than interpreting a genetic result in isolation.
The Bigger Picture: Genetics and Preventive Cardiology
The RYR2–CPVT relationship illustrates a broader change in medicine.
Genetic testing is increasingly moving from simply answering “What disease does this person have?” toward helping clinicians understand:
- Why a patient developed a particular condition
- Whether a cardiac disorder may be inherited
- Which relatives may need evaluation
- How clinical findings and genetic information fit together
- How surveillance and management can be personalized
For inherited arrhythmias, this approach can be particularly important because symptoms may occur before obvious structural heart disease develops.
When Should You Discuss RYR2 Testing With a Doctor?
Consider discussing inherited arrhythmia evaluation with a qualified healthcare professional if there is:
- Unexplained fainting during exercise
- Exercise- or emotion-triggered palpitations
- Documented unexplained ventricular arrhythmia
- A family history of unexplained sudden cardiac death at a young age
- A known disease-causing RYR2 variant in the family
Genetic testing should be ordered and interpreted in an appropriate clinical context. A positive result does not replace cardiac assessment, and a negative result does not necessarily exclude every inherited cause of arrhythmia
Exploring RYR2 Genetic Testing
For patients in whom a clinician suspects an inherited arrhythmia such as CPVT, RYR2 genetic testing can provide important molecular information that complements cardiac evaluation.
DNA Labs Nigeria currently provides an RYR2 NGS genetic test specifically described for investigating RYR2-associated catecholaminergic polymorphic ventricular tachycardia. The laboratory’s test page provides further information about the test and its clinical context.
Explore the RYR2 Gene NGS Genetic DNA Test at DNA Labs Nigeria FAQs
FAQS:
1. What is RYR2 genetic testing?
RYR2 genetic testing analyzes the RYR2 gene for genetic variants associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited cardiac rhythm disorder. RYR2 is the most frequently implicated gene in typical CPVT.
2. What is CPVT?
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia in which abnormal ventricular rhythms can occur during physical exercise or emotional stress. The condition may occur despite a structurally normal heart and a normal resting ECG.
3. Who should consider RYR2 genetic testing?
RYR2 testing may be appropriate for people whose clinical evaluation suggests CPVT, particularly those with exercise- or emotion-related syncope, characteristic ventricular arrhythmias, or a relevant family history. Genetic testing should be guided by a qualified cardiologist or genetics professional.
4. Can a person have CPVT with a normal ECG?
Yes. A resting ECG is often normal in CPVT. Exercise testing is particularly important because characteristic arrhythmias may emerge when the heart is exposed to increased adrenergic stimulation.
5. Can RYR2 mutations cause sudden cardiac death?
Certain pathogenic RYR2 variants are associated with CPVT, which can cause serious ventricular arrhythmias and, in severe cases, cardiac arrest or sudden cardiac
